Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Public ClinicalTrials.gov record NCT03755804. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk groups.
Study identification
- NCT ID
- NCT03755804
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 232 participants
Conditions and interventions
Conditions
Interventions
- bendamustine Drug
- Etoposide Drug
- Doxorubicin Drug
- Bleomycin Drug
- Vincristine Drug
- Vinblastine Drug
- Prednisone Drug
- Filgrastim Drug
- Brentuximab Vedotin Drug
- Cyclophosphamide Drug
- DTIC Drug
- Quality of Life Measurements Other
- Radiotherapy Radiation
Drug · Other · Radiation
Eligibility (public fields only)
- Age range
- Up to 25 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2018
- Primary completion
- Dec 31, 2026
- Completion
- Jun 30, 2028
- Last update posted
- Jun 16, 2026
2018 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lucile Packard Children's Hospital Stanford University | Palo Alto | California | 94304 | — |
| St. Jude Midwest Affiliate - Peoria | Peoria | Illinois | 61637 | — |
| St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center) | Baton Rouge | Louisiana | 70809 | — |
| Maine Children's Cancer Program | Scarborough | Maine | 04074 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital | Charlotte | North Carolina | 28204 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03755804, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03755804 live on ClinicalTrials.gov.